[HTML][HTML] IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice

P Gasse, C Mary, I Guenon, N Noulin… - The Journal of …, 2007 - Am Soc Clin Investig
P Gasse, C Mary, I Guenon, N Noulin, S Charron, S Schnyder-Candrian, B Schnyder…
The Journal of clinical investigation, 2007Am Soc Clin Investig
The molecular mechanisms of acute lung injury resulting in inflammation and fibrosis are not
well established. Here we investigate the roles of the IL-1 receptor 1 (IL-1R1) and the
common adaptor for Toll/IL-1R signal transduction, MyD88, in this process using a murine
model of acute pulmonary injury. Bleomycin insult results in expression of neutrophil and
lymphocyte chemotactic factors, chronic inflammation, remodeling, and fibrosis. We
demonstrate that these end points were attenuated in the lungs of IL-1R1–and MyD88 …
The molecular mechanisms of acute lung injury resulting in inflammation and fibrosis are not well established. Here we investigate the roles of the IL-1 receptor 1 (IL-1R1) and the common adaptor for Toll/IL-1R signal transduction, MyD88, in this process using a murine model of acute pulmonary injury. Bleomycin insult results in expression of neutrophil and lymphocyte chemotactic factors, chronic inflammation, remodeling, and fibrosis. We demonstrate that these end points were attenuated in the lungs of IL-1R1– and MyD88-deficient mice. Further, in bone marrow chimera experiments, bleomycin-induced inflammation required primarily MyD88 signaling from radioresistant resident cells. Exogenous rIL-1β recapitulated a high degree of bleomycin-induced lung pathology, and specific blockade of IL-1R1 by IL-1 receptor antagonist dramatically reduced bleomycin-induced inflammation. Finally, we found that lung IL-1β production and inflammation in response to bleomycin required ASC, an inflammasome adaptor molecule. In conclusion, bleomycin-induced lung pathology required the inflammasome and IL-1R1/MyD88 signaling, and IL-1 represented a critical effector of pathology and therapeutic target of chronic lung inflammation and fibrosis.
The Journal of Clinical Investigation